Published in Neurology on August 11, 1999
Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain (2008) 3.05
Dirty-appearing white matter in multiple sclerosis: preliminary observations of myelin phospholipid and axonal loss. J Neurol (2008) 1.51
Cognitive impairment in probable multiple sclerosis. J Neurol Neurosurg Psychiatry (2003) 1.28
Deficient MWF mapping in multiple sclerosis using 3D whole-brain multi-component relaxation MRI. Neuroimage (2011) 1.17
Translational research in central nervous system drug discovery. NeuroRx (2005) 1.12
The differential diagnosis of multiple sclerosis. J Neurol Neurosurg Psychiatry (2001) 1.04
Tumefactive demyelinating lesions: nine cases and a review of the literature. Neurosurg Rev (2009) 1.00
Immunomodulatory treatment strategies in multiple sclerosis. J Neurol (2008) 0.99
Imaging of multiple sclerosis: role in neurotherapeutics. NeuroRx (2005) 0.98
T2 relaxation time analysis in patients with multiple sclerosis: correlation with magnetization transfer ratio. Eur Radiol (2003) 0.94
Identification of molecular biomarkers for multiple sclerosis. J Mol Diagn (2007) 0.92
Non-locally regularized segmentation of multiple sclerosis lesion from multi-channel MRI data. Magn Reson Imaging (2014) 0.90
Improved differentiation between MS and vascular brain lesions using FLAIR* at 7 Tesla. Eur Radiol (2013) 0.88
Escalating immunotherapy of multiple sclerosis--new aspects and practical application. J Neurol (2004) 0.88
Rotation-invariant multi-contrast non-local means for MS lesion segmentation. Neuroimage Clin (2015) 0.86
Quantification of magnetization transfer rate and native T1 relaxation time of the brain: correlation with magnetization transfer ratio measurements in patients with multiple sclerosis. Neuroradiology (2005) 0.85
Evidence from clinical trials: can we do better? NeuroRx (2004) 0.83
MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain : A review of reported findings. J Neurol (2007) 0.83
Metabolomic approach to human brain spectroscopy identifies associations between clinical features and the frontal lobe metabolome in multiple sclerosis. Neuroimage (2013) 0.82
Clone clusters in autoreactive CD4 T-cell lines from probable multiple sclerosis patients form disease-characteristic signatures. Immunology (2009) 0.81
The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis. Prog Neurobiol (2015) 0.79
Non-Local Means Inpainting of MS Lesions in Longitudinal Image Processing. Front Neurosci (2015) 0.79
Multi-Sectional Views Textural Based SVM for MS Lesion Segmentation in Multi-Channels MRIs. Open Biomed Eng J (2012) 0.79
Multiple sclerosis therapy: an update on recently finished trials. J Neurol (2007) 0.78
Improved short tau inversion recovery (iSTIR) for increased tumor conspicuity in the abdomen. MAGMA (2013) 0.75
MRI utility in the detection of disease activity in clinically stable patients with multiple sclerosis: a retrospective analysis of a community based cohort. BMC Neurol (2016) 0.75
Activities of daily living and lesion position among multiple sclerosis patients by Bayes network. Neural Regen Res (2013) 0.75
Idiopathic Transverse Myelitis Mimicking an Intramedullary Spinal Cord Tumor. Case Rep Pathol (2016) 0.75
Application of Texture Analysis in Diagnosis of Multiple Sclerosis by Magnetic Resonance Imaging. Glob J Health Sci (2015) 0.75
New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol (1983) 26.67
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol (2001) 24.36
Consistent resting-state networks across healthy subjects. Proc Natl Acad Sci U S A (2006) 19.60
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol (1996) 10.39
Delayed visual evoked response in optic neuritis. Lancet (1972) 6.11
A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke (2001) 5.81
Visual evoked response in diagnosis of multiple sclerosis. Br Med J (1973) 5.61
Reduced resting-state brain activity in the "default network" in normal aging. Cereb Cortex (2007) 5.28
Diagnosis and classification of multiple sclerosis. Br Med Bull (1977) 4.68
Hydroxyproline arabinosides in the plant kingdom. Plant Physiol (1971) 4.67
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet (2001) 4.55
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med (2000) 4.50
Oral contraceptives and cerebral arterial occlusion. Br Med J (1965) 4.42
Immunological aspects of demyelinating diseases. Annu Rev Immunol (1992) 4.39
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology (2006) 4.38
The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med (1993) 4.34
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology (2011) 4.25
Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry (1992) 4.16
Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med (2000) 3.98
Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency. Neurology (2010) 3.98
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain (1997) 3.87
Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nat Med (1997) 3.65
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37
Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc Natl Acad Sci U S A (1998) 3.35
The effects of experimental demyelination on conduction in the central nervous system. Brain (1970) 3.31
Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28
Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. Neuroimage (2004) 3.25
Genetic heterogeneity and mitochondrial DNA heteroplasmy in Leber's hereditary optic neuropathy. J Med Genet (1989) 3.25
The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology (2003) 3.21
A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci (1993) 3.16
The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study. Brain (1987) 3.15
In vivo measurement of T2 distributions and water contents in normal human brain. Magn Reson Med (1997) 3.11
Central nervous system sarcoidosis--diagnosis and management. QJM (1999) 3.11
A full genome search in multiple sclerosis. Nat Genet (1996) 2.96
Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology (1996) 2.94
Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology (2007) 2.88
Slow virus replication: the role of macrophages in the persistence and expression of visna viruses of sheep and goats. J Gen Virol (1982) 2.87
The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain (2000) 2.84
Cortical lesions in multiple sclerosis. Brain (1999) 2.83
Incident lacunes influence cognitive decline: the LADIS study. Neurology (2011) 2.81
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology (2006) 2.75
White matter damage in Alzheimer's disease assessed in vivo using diffusion tensor magnetic resonance imaging. J Neurol Neurosurg Psychiatry (2002) 2.72
A comprehensive study of gray matter loss in patients with Alzheimer's disease using optimized voxel-based morphometry. Neuroimage (2003) 2.67
Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain (2008) 2.67
Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis. Neurology (2011) 2.65
Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol (1984) 2.64
Occurrence of a multiple sclerosis-like illness in women who have a Leber's hereditary optic neuropathy mitochondrial DNA mutation. Brain (1992) 2.62
Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol (1999) 2.61
A population-based study of multiple sclerosis in twins. N Engl J Med (1986) 2.59
Failure of 3,4-diaminopyridine to reverse conduction block in inflammatory demyelinating neuropathies. Ann Neurol (1993) 2.56
Age-dependent resistance to viral encephalitis: studies of infections due to Sindbis virus in mice. J Infect Dis (1972) 2.56
Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis. Neurology (1999) 2.54
Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain (1996) 2.54
Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain (1990) 2.53
Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria. J Am Coll Cardiol (1985) 2.50
Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology (2000) 2.47
Diffusion tensor imaging can detect and quantify corticospinal tract degeneration after stroke. J Neurol Neurosurg Psychiatry (2000) 2.44
Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging. Radiology (1992) 2.41
The persistent vegetative state. BMJ (1995) 2.35
Cause of death in patients attending multiple sclerosis clinics. Neurology (1991) 2.33
Management of acute optic neuritis. Lancet (2002) 2.33
Prevalence and severity of microbleeds in a memory clinic setting. Neurology (2006) 2.29
Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain (1988) 2.29
Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Neurology (2011) 2.26
Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol (1991) 2.25
Measles virus-specific T4+ human cytotoxic T cell clones are restricted by class II HLA antigens. J Immunol (1984) 2.21
Alexander disease: ventricular garlands and abnormalities of the medulla and spinal cord. Neurology (2006) 2.19
Factors influencing the risk of multiple sclerosis developing in patients with optic neuritis. Brain (1978) 2.19
Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology (1998) 2.17
Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI. Neurology (2011) 2.17
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology (2007) 2.17
Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG) Neurology (1998) 2.16
Postmortem verification of MS cortical lesion detection with 3D DIR. Neurology (2012) 2.16
Pattern of brain tissue loss associated with freezing of gait in Parkinson disease. Neurology (2012) 2.13
Hydroxyproline heterooligosaccharides in Chlamydomonas. Science (1972) 2.12
Myelin water imaging in multiple sclerosis: quantitative correlations with histopathology. Mult Scler (2006) 2.12
Identification of candidate T-cell epitopes and molecular mimics in chronic Lyme disease. Nat Med (1999) 2.11
Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology (2008) 2.11
HLA class II-restricted presentation of cytoplasmic measles virus antigens to cytotoxic T cells. J Virol (1989) 2.11
Intracranial hematomas: imaging by high-field MR. Radiology (1985) 2.08